The ACVR1 Knockout HEK293T Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population generated from the widely used HEK293T host cell line. By disrupting the ACVR1 gene encoding the type I BMP receptor activin A receptor type 1 (also known as ALK2), these polyclonal knockout cells provide a loss-of-function model to dissect BMP signaling pathways. The polyclonal nature of the product offers a heterogeneous pool of edited cells, enabling robust and reproducible experimental outcomes without clonal selection artifacts. This product serves as a valuable tool for studying BMP-dependent processes in a human cellular context, particularly when combined with the high transfectability of HEK293T cells.
HEK293T is a human embryonic kidney epithelial cell line that stably expresses the SV40 large T antigen, which facilitates episomal replication of plasmids containing the SV40 origin of replication. This feature, along with its high transfection efficiency and robust protein expression capacity, has made HEK293T a workhorse for recombinant protein production, viral packaging, and functional assays. The epithelial origin and the presence of key signaling components allow these cells to respond to various growth factors, including BMP ligands, making them a suitable platform for investigating receptor function and downstream signaling cascades.
ACVR1 functions as a type I BMP receptor possessing serine/threonine kinase activity that phosphorylates receptor-regulated SMADs upon ligand binding. The receptor is activated by BMP ligands such as BMP2, BMP4, BMP6, and BMP7, and inhibited by antagonists like follistatin, noggin, and chordin. Upon activation, ACVR1, in complex with the type II receptor BMPR2 and co-receptors including endoglin and betaglycan, phosphorylates SMAD1, SMAD5, and SMAD8. These phosphorylated SMADs then form heteromeric complexes with SMAD4 and translocate to the nucleus to regulate transcription of target genes, including ID1, ID2, HAMP (hepcidin), Osterix (SP7), and Runx2. This canonical BMP-SMAD pathway is central to osteogenesis, embryogenesis, and iron homeostasis. Negative regulation is mediated by factors such as FKBP12, SMURF1, and Arkadia.
In HEK293T cells, ACVR1 knockout ablates BMP-induced SMAD1/5/8 phosphorylation, thereby blocking downstream transcriptional responses. This model allows researchers to dissect the specific contributions of ACVR1-mediated signaling in a simplified cellular environment, free from the complexities of primary cells. Because HEK293T cells lack the endogenous expression of many BMP-responsive differentiation programs, the knockout model is particularly useful for reconstitution experiments and pathway dissection using reporter assays or overexpression of downstream effectors. It also provides a clean background for studying gain-of-function mutations associated with fibrodysplasia ossificans progressiva (FOP), where inappropriate ACVR1 activation drives heterotopic ossification.
Researchers can employ these ACVR1 knockout HEK293T polyclonal cells in a variety of experimental settings. Applications include BMP-responsive luciferase reporter gene assays to quantify pathway activity, western blotting and phospho-flow cytometry to measure SMAD1/5 phosphorylation, co-immunoprecipitation studies to probe receptor complex assembly, and RT-qPCR analysis of target gene expression such as ID1 or HAMP. The model is also highly suitable for screening small-molecule ACVR1 inhibitors for therapeutic development in FOP and iron-refractory iron deficiency anemia. Additionally, it supports investigation of osteogenic differentiation and cross-talk with TGF-beta signaling. For further information or to discuss custom applications, please contact Ascent Research.
